Reason for request
Re-assessment of methylphenidate-based proprietary products in attention-deficit hyperactivity disorder in response to a request from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of CONCERTA LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years and over when psychological, educational and social management alone prove insufficient. |
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
m6VxAGSYn7h08K9r
